



Sample **Mimosa - X11**

Delta9 THC	UI	THCa	ND	Total THC (THC + THCa)	UI	Delta8 THC	431.05%
------------	----	------	----	------------------------	----	------------	---------

Sample ID	SD220902-039 (51973)	Matrix	Concentrate (Inhalable Cannabis Good)
Tested for	Latro inc		
Sampled	-	Received	Sep 02, 2022
Analyses executed	CANX	Reported	Sep 27, 2022
		Unit Mass (g)	2.5

Laboratory note: The estimated concentration of the unknown peak in the sample is 4.9% | Currently PharmLabs laboratory can not confirm an unidentified peak in your chromatogram due to interference (only with highly concentrated D8 products) from which we believe to be either (+)Δ8-THC or Δ9-THC. At this time there are no reference standards available for (+)Δ8-THC. (+)Δ8-THC is a different compound from the main (-)Δ8-THC cannabinoid and, therefore, these two compounds may have different efficacies. Using the most advanced instruments and techniques available, the separation of (+)Δ8-THC and Δ9-THC is problematic for the scientific community as a whole. PharmLabs believes the unidentified peak to be a combination of (+)Δ8-THC and Δ9-THC with the majority, if not all, of the concentration being (+)Δ8-THC. Total Δ8-THC is estimated to be 48.0%.

CANX - Cannabinoids Analysis

Analyzed Sep 06, 2022 | Instrument HPLC-VWD | Method SOP-001

The expanded Uncertainty of the Cannabinoid analysis is approximately $\pm 8.06\%$ at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabivarin (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND
Cannabidiol (CBDO)	0.002	0.007	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.01	0.031	ND	ND	ND
(+/-)-9B-hydroxy-Hexahydrocannabinol (9b-HHC)	0.012	0.036	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.007	0.021	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.001	0.16	1.81	18.07	45.18
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND	ND
Cannabigerol (CBG)	0.001	0.16	ND	ND	ND
Cannabidiol (CBD)	0.001	0.16	5.56	55.60	139.00
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.013	0.041	ND	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.025	0.075	ND	ND	ND
Tetrahydrocannabivarin (THCV)	0.001	0.16	ND	ND	ND
Δ8-tetrahydrocannabivarin (Δ8-THCV)	0.021	0.064	ND	ND	ND
Tetrahydrocannabinol (Δ9-THCB)	0.013	0.038	ND	ND	ND
Cannabinol (CBN)	0.001	0.16	1.22	12.17	30.42
exo-THC (exo-THC)	0.005	0.16	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.003	0.16	UI	UI	UI
Δ8-tetrahydrocannabinol (Δ8-THC)	0.004	0.16	43.11	431.05	1077.63
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.16	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.16	9.70	97.04	242.61
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.16	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.16	9.06	90.58	226.44
Tetrahydrocannabinolic Acid (THCA)	0.001	0.16	ND	ND	ND
Δ9-Tetrahydrocannabihexol (Δ9-THCH)	0.024	0.071	ND	ND	ND
Cannabinol Acetate (CBNO)	0.014	0.043	ND	ND	ND
Δ9-Tetrahydrocannabiphoral (Δ9-THCP)	0.017	0.16	7.91	79.06	197.64
Δ8-Tetrahydrocannabiphoral (Δ8-THCP)	0.041	0.16	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.16	2.80	28.00	70.01
9(S)-HHCP (s-HHCP)	0.031	0.094	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.16	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.026	0.079	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	ND	ND	ND
Cannabichromene (CBC)	0.002	0.16	ND	ND	ND
Cannabidivarin (CBDV)	0.039	0.16	ND	ND	ND
11-Hydroxy-Δ9-tetrahydrocannabinol (11-OH-Δ9-THC)			ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			UI	UI	UI
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			43.11	431.05	1077.63
Total CBD (CBDA * 0.877 + CBD)			7.14	71.45	178.62
Total CBG (CBGA * 0.877 + CBG)			ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			18.76	187.62	469.06
Total Cannabinoids Analyzed			80.94	809.35	2023.38

UI Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



DCC license: C8-0000098-LIC
DEA license: RP0611043
ISO/IEC 17025:2017 Acc. L17-427-1



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager
Tue, 27 Sep 2022 16:33:30 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1



*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.